Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LKY-047, a derivative of Decursin, is a highly effective and specific reversible competitive inhibitor of cytochrome P45022J2 (CYP2J2), with an IC 50 value of 1.7 μM. LKY-047 does not display inhibitory activity against other human P450 enzymes including CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A.
产品描述 | LKY-047, a derivative of Decursin, is a highly effective and specific reversible competitive inhibitor of cytochrome P45022J2 (CYP2J2), with an IC 50 value of 1.7 μM. LKY-047 does not display inhibitory activity against other human P450 enzymes including CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A. |
靶点活性 | CYP2J2:1.7 μM (IC50) |
体外活性 | LKY-047 is a strong competitive inhibitor of CYP2J2-mediated astemizole O-demethylase and terfenadine hydroxylase activity, with K i values of 0.96 μM and 2.61 μM, respectively. LKY-047 also acted as an uncompetitive inhibitor of CYP2J2-mediated ebastine hydroxylation with a K i value of 3.61 μM[1]. At 20 μM LKY-047 concentration, approximately 20-fold greater than the Ki value, LKY-047 is found to inhibit CYP2J2 by 85.3%, and only slightly affecting the enzyme activities of the other P450s tested. LKY-047 weakly inhibits CYP2D6 enzyme activity (37.2%) at 20 μM concentration[1]. |
分子量 | 421.405 |
分子式 | C23H19NO7 |
CAS No. | 1954681-29-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
LKY-047 1954681-29-8 LKY 047 LKY047 Inhibitor inhibitor inhibit